Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2436 results

Gilead and Ono enter into a licensing agreement for ONO-4059

Gilead and Ono enter into a licensing agreement for ONO-4059

19-12-2014

Japanese pharma company Ono Pharmaceutical and US biotech major Gilead Sciences have entered into a licensing…

BiotechnologyGilead SciencesLicensingOncologyOno PharmaceuticalONO-4059Research

Sorrento and Conkwest join forces on cancer immunotherapies development

19-12-2014

US cancer drug developer Sorrento Therapeutic and privately-held Conkwest have entered into a definitive…

BiotechnologyConkwestFinancialNeukoplastOncologyResearchSorrento Therapeutics

Merck & Co in up to $375 million deal to acquire OncoEthix

Merck & Co in up to $375 million deal to acquire OncoEthix

19-12-2014

US pharma giant Merck & Co said yesterday that it has acquired, through a subsidiary, Swiss-based privately…

BiotechnologyMerck & CoMergers & AcquisitionsOncoEthixOncologyOTX015

Roche to acquire Austrian next-generation antibody firm Dutalys

Roche to acquire Austrian next-generation antibody firm Dutalys

19-12-2014

Swiss pharma giant Roche has agreed to acquire Dutalys, a privately held biotechnology company based…

BiotechnologyDutalysDutaMabMergers & AcquisitionsOncologyRoche

France Biotech presents twelfth annual Panorama of the Life Sciences survey results

France Biotech presents twelfth annual Panorama of the Life Sciences survey results

18-12-2014

France Biotech, an association for life sciences entrepreneurs, has published the twelfth edition of…

BiotechnologyFrancePoliticsProductionResearch

Claritas Genomics appoints Patrick Terry as chief commercial officer

Claritas Genomics appoints Patrick Terry as chief commercial officer

18-12-2014

Genetic diagnostic lab, Claritas Genomics, has appointed Patrick Terry as chief commercial officer.

BiotechnologyBoardroomClaritas GenomicsGenomicsPatrick Terry

Amgen reveals Blincyto price as $178,000 per course

Amgen reveals Blincyto price as $178,000 per course

18-12-2014

USA-based Amgen has revealed its intended pricing for its immunotherapy Blincyto (blinatumomab), which…

AmgenBiotechnologyBlincytoOncologyPricingUSA

X-Chem licenses second cardiovascular drug discovery program to Bayer

X-Chem licenses second cardiovascular drug discovery program to Bayer

18-12-2014

Privately-held biotech firm X-Chem has licensed a second drug discovery program to German pharma major…

BayerBiotechnologyCardio-vascularLicensingX-Chem

Novartis venture fund leads $34 million financing for Annexon Bioscience

Novartis venture fund leads $34 million financing for Annexon Bioscience

17-12-2014

USA-based Annexon Bioscience says it has closed a $34 million Series A-1 to support the development of…

Annexon BioscienceANX005BiotechnologyFinancialNeurologicalNovartis

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

16-12-2014

Denmark and USA-based contract manufacturers CMC Biologics and US biopharma start-up OncoSynergy have…

Anti-viralsBiotechnologyCMC BiologicsOncoSynergyOS2966ProductionResearchTropical diseases

Neovacs' Phase IIb study of TNF-Kinoid in rheumatoid arthritis fails to meet primary endpoints

Neovacs' Phase IIb study of TNF-Kinoid in rheumatoid arthritis fails to meet primary endpoints

16-12-2014

French autoimmune specialist Neovacs says that its Phase IIb trial of TNF-Kinoid in rheumatoid arthritis…

BiotechnologyFranceImmunologicalsNeovacsResearchTNF-Kinoid

Curie-Cancer renews research partnership with GamaMabs Pharma for ovarian cancer drug

Curie-Cancer renews research partnership with GamaMabs Pharma for ovarian cancer drug

16-12-2014

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities,…

BiotechnologyFranceGamaMabs PharmaOncologyResearch

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

16-12-2014

US development-stage biophama company Anthera Pharmaceuticals has entered into an exclusive licensing…

AmgenAnthera PharmaceuticalsBiotechnologyblisibimodJapanLicensingOncologyZenyaku Kogyo

Sophiris Bio shares slide on Phase III results of PRX302

Sophiris Bio shares slide on Phase III results of PRX302

16-12-2014

Biotech company Sophiris Bio saw shares in the company fall up to almost 80% following an announcement…

BiotechnologyMen's HealthPRX302ResearchSophiris Bio

Astellas Venture Management invests in Crescendo's Humabody antibody fragment project

Astellas Venture Management invests in Crescendo's Humabody antibody fragment project

16-12-2014

UK-based antibody therapeutics specialist Crescendo Biologics has received another equity investment…

BiotechnologyBusiness FinanceCrescendo BiologicsOncologyUK

New $11 million Biotech Innovation Hub opens in Birmingham, UK

New $11 million Biotech Innovation Hub opens in Birmingham, UK

16-12-2014

A new biomedical laboratory, the Biomedical Innovation Hub (the BioHub) has opened in Birmingham, UK.

BiotechnologyBirminghamResearchUKUnited Kingdom

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

15-12-2014

Oncology specialist Sorrento Therapeutics has entered into a binding agreement with medical technology…

BiotechnologyLicensingOncologyResearchSorrento TherapeuticsUSA

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

15-12-2014

Genentech, the US biotech subsidiary of Swiss Pharma major Roche Group, has submitted a New Drug Application…

BiotechnologycobimetinibExelixisGenentechOncologyRegulationRocheUSAZelboraf

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

15-12-2014

US biotech major Gilead Sciences has appointed Philippe Bishop as senior vice president of hematology…

BiotechnologyBoardroomGilead SciencesHematologyOncologyUSA

Ignyta and Nerviano amend license accord on entrectinib

Ignyta and Nerviano amend license accord on entrectinib

15-12-2014

US oncology focused biotech firm Ignyta has agreed to an amendment to its license agreement with Italy’s…

BiotechnologyentrectinibIgnytaLicensingNerviano Medical SciencesOncologyRXDX-101

Zealand Pharma's senior vice president Arvind Hundal steps down

Zealand Pharma's senior vice president Arvind Hundal steps down

15-12-2014

Denmark-based biotech company Zealand Pharma announced today that senior vice president and chief business…

Arvind HundalBiotechnologyBoardroomDenmarkZealand Pharma

1 to 25 of 2436 results

Back to top